Check point inhibitors a new era in renal cell carcinoma treatment

2018 ◽  
Vol 35 (6) ◽  
Author(s):  
Mohamed Alsharedi ◽  
Heather Katz
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Check Point ◽  
New Era ◽  
Check Point Inhibitors

scholarly journals Soluble forms of the immune check-point receptor PD-1 and its ligand PD-L1 in blood serum of patients with renal cell carcinoma: clinical and pathologic correlations

2019 ◽  
Vol 15 (1) ◽  
pp. 15-22 ◽  
Author(s):  
N. E. Kushlinskii ◽  
E. S. Gershtein ◽  
I. O. Goryatcheva ◽  
A. A. Morozov ◽  
A. A. Alferov ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Blood Serum ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Check Point

scholarly journals Nivolumab: 5 Years Since FDA Approval of the First Checkpoint Inhibitor for Renal Cell Carcinoma

Kidney Cancer ◽  
2021 ◽  
pp. 1-9
Author(s):  
Ilya Tsimafeyeu
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Drug Administration ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Checkpoint Inhibitor ◽  
Food And Drug Administration ◽  
New Era ◽  
Fda Approval ◽  
The Us

On November 23, 2015, the US Food and Drug Administration (FDA) approved nivolumab for the treatment of metastatic renal cell carcinoma (RCC), thus opening a new era of immunotherapy for this tumor. This review summarizes the 5-year experience of studying and using nivolumab in RCC patients.

Renal Cell Carcinoma: A New Era?

2005 ◽  
Vol 4 (3) ◽  
pp. 155 ◽  
Author(s):  
Ronald M. Bukowski
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
New Era

ATP-competitive inhibitors of mTOR: new perspectives in the treatment of renal cell carcinoma

2011 ◽  
Vol 39 (2) ◽  
pp. 492-494 ◽  
Author(s):  
Didier Roulin ◽  
Nicolas Demartines ◽  
Olivier Dormond
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Mammalian Target Of Rapamycin ◽  
Mechanisms Of Action ◽  
Target Of Rapamycin ◽  
New Era ◽  
Biological Relevance ◽  
Competitive Inhibitors

Targeting mTOR (mammalian target of rapamycin) is an effective approach in the treatment of advanced RCC (renal cell carcinoma). Rapamycin-like drugs (rapalogues) have shown clinical activities and have been approved for the treatment of RCC. Recently, with the development of ATP-competitive inhibitors of mTOR, therapies targeting mTOR have entered a new era. Here, we discuss the biological relevance of blocking mTOR in RCC and review the mechanisms of action of rapalogues in RCC. We also advance some perspectives on the use of ATP-competitive inhibitors of mTOR in RCC.

Immune Check Point Inhibition in Sarcomatoid Renal Cell Carcinoma: A New Treatment Paradigm

2017 ◽  
Vol 15 (5) ◽  
pp. e897-e901 ◽  
Author(s):  
Ruben Raychaudhuri ◽  
Matthew J. Riese ◽  
Kathryn Bylow ◽  
John Burfeind ◽  
Alexander C. Mackinnon ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Check Point ◽  
Treatment Paradigm ◽  
Sarcomatoid Renal Cell Carcinoma ◽  
New Treatment
Sign in / Sign up

Export Citation Format

Share Document